Cargando…

Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification

Crizotinib has been used to counter MET gene amplification in a number of different human malignancies. Transient response to crizotinib in MET-amplified gastric cancer has been reported, but the mechanisms of resistance are not well studied. Here, we reported a stage IV gastric cancer patient with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Juan, Wu, Xue, Tong, Xiaoling, Wang, Xiaonan, Wei, Jia, Yang, Yang, Chang, Zhili, Mao, Yu, Shao, Yang W, Liu, Baorui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432256/ https://www.ncbi.nlm.nih.gov/pubmed/28460431 http://dx.doi.org/10.18632/oncotarget.15457

Ejemplares similares

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
por: Peng, Lun-Xi, et al.
Publicado: (2021)

Combination treatment with trastuzumab and crizotinib in metastatic gastric cancer harboring Her-2 amplification and c-MET amplification: A case report
por: Liu, Mingsheng
Publicado: (2021)

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types
por: Shu, Yongqian, et al.
Publicado: (2017)

A case report of response to crizotinib in chemotherapy-refractory metastatic gallbladder cancer with met amplification and acquired resistance resulting from the loss of MET amplification
por: Sun, Hongna, et al.
Publicado: (2021)

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program
por: Aparicio, Thomas, et al.
Publicado: (2021)

Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy
por: Gu, Fei-fei, et al.
Publicado: (2016)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
por: Wang, Xiaomeng, et al.
Publicado: (2021)

Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells
por: Schroeder, Rebecca D., et al.
Publicado: (2017)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation
por: Yao, Jing-hao, et al.
Publicado: (2019)

Crizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation
por: Chen, Jin‐Jiao, et al.
Publicado: (2023)

Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization
por: Schmitt, Christina, et al.
Publicado: (2021)

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
por: Jóri, Balázs, et al.
Publicado: (2023)

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
por: Rochigneux, Philippe, et al.
Publicado: (2018)

Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
por: Sun, Boyang, et al.
Publicado: (2023)

Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report
por: Zhou, Yuling, et al.
Publicado: (2020)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report
por: Tan, Xiang, et al.
Publicado: (2017)

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib
por: Yang, Yan, et al.
Publicado: (2017)

Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification
por: Zhao, Zhi-Mei, et al.
Publicado: (2021)

Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
por: Urbanska, Edyta M., et al.
Publicado: (2023)

MET amplification as a potential therapeutic target in gastric cancer
por: Kawakami, Hisato, et al.
Publicado: (2012)

Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma
por: Lin, Jianzhen, et al.
Publicado: (2021)

A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
por: Zhu, You-cai, et al.
Publicado: (2018)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
por: Chen, Yan, et al.
Publicado: (2022)

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma
por: Zhang, Jing, et al.
Publicado: (2016)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
por: Wang, Yurong, et al.
Publicado: (2022)

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
por: Zhu, Viola W, et al.
Publicado: (2019)

TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer
por: Li, Jia, et al.
Publicado: (2021)

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
por: Palma, Norma A., et al.
Publicado: (2014)

Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer
por: Yan, Hong Hua, et al.
Publicado: (2014)

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
por: Drilon, Alexander, et al.
Publicado: (2020)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer
por: Kang, Jin, et al.
Publicado: (2018)

Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib
por: Cheng, Tianli, et al.
Publicado: (2021)

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer
por: Zeng, Liang, et al.
Publicado: (2020)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib()()()
por: Cuneo, Kyle C., et al.
Publicado: (2018)

Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report
por: Gu, Yangjun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b4dojjtiqtnbntecan8lpm1me5